| Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line DA Tweddle, AJ Malcolm, N Bown, ADJ Pearson, J Lunec Cancer research 61 (1), 8-13, 2001 | 219 | 2001 |
| High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma J Carr-Wilkinson, K O'Toole, KM Wood, CC Challen, AG Baker, JR Board, ... Clinical cancer research 16 (4), 1108-1118, 2010 | 196 | 2010 |
| The p53 pathway and its inactivation in neuroblastoma DA Tweddle, ADJ Pearson, M Haber, MD Norris, C Xue, C Flemming, ... Cancer letters 197 (1-2), 93-98, 2003 | 196 | 2003 |
| DNA damage checkpoint kinases in cancer HL Smith, H Southgate, DA Tweddle, NJ Curtin Expert reviews in molecular medicine 22, e2, 2020 | 188 | 2020 |
| p53 is a direct transcriptional target of MYCN in neuroblastoma L Chen, N Iraci, S Gherardi, LD Gamble, KM Wood, G Perini, J Lunec, ... Cancer research 70 (4), 1377-1388, 2010 | 176 | 2010 |
| Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse J Carr, E Bell, ADJ Pearson, UR Kees, H Beris, J Lunec, DA Tweddle Cancer research 66 (4), 2138-2145, 2006 | 146 | 2006 |
| MYCN oncoprotein targets and their therapeutic potential E Bell, L Chen, T Liu, GM Marshall, J Lunec, DA Tweddle Cancer letters 293 (2), 144-157, 2010 | 138 | 2010 |
| p53 cellular localization and function in neuroblastoma: evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells DA Tweddle, AJ Malcolm, M Cole, ADJ Pearson, J Lunec The American journal of pathology 158 (6), 2067-2077, 2001 | 133 | 2001 |
| Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data M Łastowska, V Viprey, M Santibanez-Koref, I Wappler, H Peters, ... Oncogene 26 (53), 7432-7444, 2007 | 116 | 2007 |
| Neonatal neuroblastoma JPH Fisher, DA Tweddle Seminars in Fetal and Neonatal Medicine 17 (4), 207-215, 2012 | 115 | 2012 |
| Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative … G Schleiermacher, J Michon, A Ribeiro, G Pierron, V Mosseri, H Rubie, ... British journal of cancer 105 (12), 1940-1948, 2011 | 108 | 2011 |
| Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma RA Daniel, AL Rozanska, HD Thomas, EA Mulligan, Y Drew, ... Clinical Cancer Research 15 (4), 1241-1249, 2009 | 102 | 2009 |
| MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63 LD Gamble, UR Kees, DA Tweddle, J Lunec Oncogene 31 (6), 752-763, 2012 | 92 | 2012 |
| Factors associated with recurrence and survival length following relapse in patients with neuroblastoma NO Basta, GC Halliday, G Makin, J Birch, R Feltbower, N Bown, M Elliott, ... British journal of cancer 115 (9), 1048-1057, 2016 | 88 | 2016 |
| Cell cycle regulation targets of MYCN identified by gene expression microarrays E Bell, J Lunec, D Tweddle Cell cycle 6 (10), 1249-1256, 2007 | 84 | 2007 |
| Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma L Chen, RF Rousseau, SA Middleton, GL Nichols, DR Newell, J Lunec, ... Oncotarget 6 (12), 10207, 2015 | 78 | 2015 |
| MYCN amplification remains prognostically strong 20 years after its “clinical debut” SL Cohn, DA Tweddle European journal of cancer 40 (18), 2639-2642, 2004 | 74 | 2004 |
| Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly (ADP-ribose) polymerase inhibitor AG-014699 RA Daniel, AL Rozanska, EA Mulligan, Y Drew, HD Thomas, ... British journal of cancer 103 (10), 1588-1596, 2010 | 72 | 2010 |
| Development of a Real-Time Polymerase Chain Reaction Assay for Prediction of the Uptake of Meta-[131I]iodobenzylguanidine by Neuroblastoma Tumors S Carlin, RJ Mairs, AG McCluskey, DA Tweddle, A Sprigg, C Estlin, ... Clinical cancer research 9 (9), 3338-3344, 2003 | 71 | 2003 |
| The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage E Bell, R Premkumar, J Carr, X Lu, PE Lovat, UR Kees, J Lunec, ... Cell Cycle 5 (22), 2639-2647, 2006 | 68 | 2006 |
